Salbutamol, also known as albuterol and marketed as Ventolin among other names, is a medication that opens up the medium and large airways in the lungs. It is used to treat asthma including asthma attacks, exercise-induced bronchoconstriction, and chronic obstructive pulmonary disease (COPD). It may also be used to treat high blood potassium levels. Salbutamol is usually used with an inhaler or nebulizer but is also available as a pill and intravenous solution. Onset of action of the inhaled version is typically within 15 minutes and lasts for two to six hours.
(R)-(−)-salbutamol (center) and
|Trade names||Ventolin, Proventil, others|
|Synonyms||Albuterol (USAN US)|
|by mouth, inhalational, IV|
|Onset of action||<15 min (inhaled), <30 min (pill)|
|Biological half-life||3.8–6 hours|
|Duration of action||2–6 hrs|
|Chemical and physical data|
|Molar mass||239.311 g/mol|
|3D model (JSmol)|
|(what is this?)|
Common side effects include shakiness, headache, fast heart rate, dizziness, and feeling anxious. Serious side effects may include worsening bronchospasm, irregular heartbeat, and low blood potassium levels. It can be used during pregnancy and breastfeeding, but safety is not entirely clear. It is a short-acting β2 adrenergic receptor agonist which works by causing airway smooth muscles to relax.
Salbutamol was first made in 1967 in Britain and became commercially available in the UK in 1969. It was approved for medical use in the United States in 1982. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is available as a generic medication. The wholesale cost in the developing world of an inhaler which contains 200 doses is between $1.12 and $2.64 (USD) as of 2014. In the United States, it is between $25 and $50 for a typical month supply.
Salbutamol is typically used to treat bronchospasm (due to any cause – allergic asthma or exercise-induced), as well as chronic obstructive pulmonary disease. It is also one of the most common medicines used in rescue inhalers (short-term bronchodilators to alleviate asthma attacks).
As a β2 agonist, salbutamol also has use in obstetrics. Intravenous salbutamol can be used as a tocolytic to relax the uterine smooth muscle to delay premature labor. While preferred over agents such as atosiban and ritodrine, its role has largely been replaced by the calcium channel blocker nifedipine, which is more effective, better tolerated, and administered orally.
The most common side effects are fine tremor, anxiety, headache, muscle cramps, dry mouth, and palpitation. Other symptoms may include tachycardia, arrhythmia, flushing of the skin, myocardial ischemia (rare), and disturbances of sleep and behaviour. Rarely occurring, but of importance, are allergic reactions of paradoxical bronchospasms, urticaria (hives), angioedema, hypotension, and collapse. High doses or prolonged use may cause hypokalemia, which is of concern especially in patients with renal failure and those on certain diuretics and xanthine derivatives.
The tertiary butyl group in salbutamol makes it more selective for β2 receptors, which are the predominant receptors on the bronchial smooth muscles. Activation of these receptors causes adenylyl cyclase to convert ATP to cAMP, beginning the signalling cascade that ends with the inhibition of myosin phosphorylation and lowering the intracellular concentration of calcium ions (myosin phosphorylation and calcium ions are necessary for muscle contractions). The increase in cAMP also inhibits inflammatory cells in the airway, such as basophils, eosinophils, and most especially mast cells, from releasing inflammatory mediators and cytokines. Salbutamol and other β2 receptor agonists also increase the conductance of channels sensitive to calcium and potassium ions, leading to hyperpolarization and relaxation of bronchial smooth muscles.
Salbutamol is either filtered out by the kidneys directly or is first metabolized into 4'-O-sulphate, which is excreted in the urine.
Structure and activityEdit
Salbutamol is sold as a racemic mixture. The (R)-(−)-enantiomer (CIP nomenclature) is shown in the image at right (top), and is responsible for the pharmacologic activity; the (S)-(+)-enantiomer (bottom) blocks metabolic pathways associated with elimination of itself and of the pharmacologically active enantiomer (R). The slower metabolism of the (S)-(+)-enantiomer also causes it to accumulate in the lungs, which can cause airway hyperreactivity and inflammation.
Society and cultureEdit
The wholesale cost of a 200-dose inhaler is between $1.12 and $2.64 (USD) in the developing world as of 2014[update] and GB£1.50 in the United Kingdom as of 2015[update]. In the United States, a typical month supply is between $25 and $50.
Salbutamol is the INN (international nonproprietary name) while albuterol is the USAN (United States adopted name). The drug is usually manufactured and distributed as the sulphate salt (salbutamol sulphate).
There is no compelling evidence that salbutamol and other β2 agonists can increase performance in healthy athletes. In spite of this, salbutamol required "a declaration of Use in accordance with the International Standard for Therapeutic Use Exemptions" under the 2010 WADA prohibited list. This requirement was relaxed when the 2011 list was published to permit the use of "salbutamol (maximum 1600 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers’ recommended therapeutic regimen."
Another study contradicts the above findings, however. The double blind, randomised test conducted on 12 non-asthmatic athletes concluded that salbutamol had a negligible effect on endurance performance. Nevertheless, the study also showed that the drug's bronchodilating effect may have improved respiratory adaptation at the beginning of exercise.
Salbutamol has been shown to improve muscle weight in rats and anecdotal reports hypothesise that it might be an alternative to clenbuterol for purposes of fat burning and muscle gain, with multiple studies supporting this claim. Abuse of the drug may be confirmed by detection of its presence in plasma or urine, typically exceeding 1000 µg/L. The window of detection for urine testing is on the order of just 24 hours, given the relatively short elimination half-life of the drug, estimated at between 5 and 6 hours following oral administration of 4 mg.
It has also been tested in a trial aimed at treatment of spinal muscular atrophy; it is speculated to modulate the alternative splicing of the SMN2 gene, increasing the amount of the SMN protein whose deficiency is regarded as a cause of the disease.
Salbutamol's low toxicity makes it safe for other animals and thus is the medication of choice for treating acute airway obstruction in most species. It is usually used to treat bronchospasm or coughs in cats and dogs and used as a bronchodilator in horses with recurrent airway obstruction; it can also be used in emergencies to treat asthmatic cats.
Toxic effects require an extremely high dose, and most overdoses are due to dogs chewing on and puncturing an inhaler or nebulizer vial.
- Thereaputic Goods Administration. "Prescribing medicines in pregnancy database". Australian Government.
- "HSDB:Albuterol". ToxNet. US National Library of Medicine.
- "Salbutamol". Drugs.com. Archived from the original on 2016-03-30. Retrieved April 11, 2016.
- Thereaputic Goods Administration. "Poisons Standard June 2017". Australian Government.
- "Prescription Drug List". Government of Canada.
- "Albuterol". Drugs.com. The American Society of Health-System Pharmacists. Archived from the original on 2015-12-08. Retrieved Dec 2, 2015.
- Mahoney, BA; Smith, WA; Lo, DS; Tsoi, K; Tonelli, M; Clase, CM (18 April 2005). "Emergency interventions for hyperkalaemia.". The Cochrane database of systematic reviews (2): CD003235. PMID 15846652. doi:10.1002/14651858.CD003235.pub2.
- Starkey, ES; Mulla, H; Sammons, HM; Pandya, HC (September 2014). "Intravenous salbutamol for childhood asthma: evidence-based medicine?" (PDF). Archives of Disease in Childhood. 99 (9): 873–7. PMID 24938536. doi:10.1136/archdischild-2013-304467. Archived (PDF) from the original on 2017-09-08.
- Yaffe, Sumner J. (2011). Drugs in pregnancy and lactation : a reference guide to fetal and neonatal risk (9th ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 32. ISBN 9781608317080. Archived from the original on 2015-12-08.
- Landau, Ralph (1999). Pharmaceutical innovation : revolutionizing human health. Philadelphia: Chemical Heritage Press. p. 226. ISBN 9780941901215. Archived from the original on 2015-12-08.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- "Salbutamol". International Drug Price Indicator Guide. Retrieved 5 December 2015.
- Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 448. ISBN 9781284057560.
- Hatfield, Heather. "Asthma: The Rescue Inhaler -- Now a Cornerstone of Asthma Treatment". WebMD. Archived from the original on 2017-07-16. Retrieved 2017-06-27.
- Rossi, S (2004). Australian Medicines Handbook. AMH. ISBN 0-9578521-4-2.
- "220.127.116.11 Selective beta2 agonists – side effects". British National Formulary (57 ed.). London: BMJ Publishing Group Ltd and Royal Pharmaceutical Society Publishing. March 2008. ISBN 0-85369-778-7.
- Lemke, T.L.; Williams, D.A.; Roche, V.F.; Zito, S.W. (2013). Foye's Principles of Medicinal Chemistry. Philadelphia, PA: Lippincott Williams & Wilkins. pp. 1314–1320. ISBN 9781609133450. OCLC 748675182. Archived from the original on 2017-09-08.
- "Albuterol Sulfate". Rx List: The Internet Drug Index. Archived from the original on 2014-07-18. Retrieved 2014-07-13.
- Papich, Mark G. (2007). "Albuterol Sulfate". Saunders Handbook of Veterinary Drugs (2nd ed.). St. Louis, Mo: Saunders/Elsevier. pp. 10–11. ISBN 9781416028888.
- US Department of Health and Human Services (2017-04-28). "Albuterol - Medical Countermeasures Database". CHEMM. Archived from the original on 2017-08-03. Retrieved 2017-06-23.
- Mehta, Akul. "Medicinal Chemistry of the Peripheral Nervous System – Adrenergics and Cholinergics their Biosynthesis, Metabolism, and Structure Activity Relationships". Archived from the original on 2010-11-04. Retrieved 2010-10-20.
- "Inhalation Therapy of Airway Disease". Merck Veterinary Manual. Archived from the original on 2017-06-25. Retrieved 2017-06-22.
- "Sir David Jack, who has died aged 87, was the scientific brain behind the rise of the pharmaceuticals company Glaxo". The Telegraph. Nov 17, 2011. Archived from the original on 2011-11-25.
- BNF 69: March 2015 - September 2015 (69 ed.). Pharmaceutical Pr. March 31, 2015. p. 190. ISBN 9780857111562.
- "Ventolin remains a breath of fresh air for asthma sufferers, after 40 years" (PDF). The Pharmaceutical Journal. 279 (7473): 404–405. Archived from the original (PDF) on Oct 15, 2007.
- Davis, E; Loiacono, R; Summers, R J (2008). "The rush to adrenaline: drugs in sport acting on the β-adrenergic system". British Journal of Pharmacology. 154 (3): 584–97. PMC . PMID 18500380. doi:10.1038/bjp.2008.164.
- "The 2010 Prohibited List International Standard" (PDF). WADA. Archived from the original (PDF) on 2013-09-11. Retrieved 2010-10-20.
- "The 2011 Prohibited List International Standard" (PDF). WADA. Archived (PDF) from the original on 2012-05-13. Retrieved 2012-05-22.
- Collomp, K; Candau, R; Lasne, F; Labsy, Z; Préfaut, C; De Ceaurriz, J (2000). "Effects of short-term oral salbutamol administration on exercise endurance and metabolism". Journal of Applied Physiology. 89 (2): 430–6. PMID 10926623. Archived from the original on 2010-11-13.
- "Salbutamol: Ergogenic effects of salbutamol". Peak Performance. Archived from the original on 2010-03-28. Retrieved 2010-10-20.
- Van Baak, MA; De Hon, OM; Hartgens, F; Kuipers, H (2004). "Inhaled salbutamol and endurance cycling performance in non-asthmatic athletes". International journal of sports medicine. 25 (7): 533–8. PMID 15459835. doi:10.1055/s-2004-815716.
- Goubault, C; Perault, MC; Leleu, E; Bouquet, S; Legros, P; Vandel, B; Denjean, A (2001). "Effects of inhaled salbutamol in exercising non-asthmatic athletes". Thorax. 56 (9): 675–679. PMC . PMID 11514686. doi:10.1136/thorax.56.9.675.
- Carter WJ, Lynch ME (September 1994). "Comparison of the effects of salbutamol and clenbuterol on skeletal muscle mass and carcass composition in senescent rats". Metab. Clin. Exp. 43 (9): 1119–25. PMID 7916118. doi:10.1016/0026-0495(94)90054-X.
- Caruso, JF; Signorile, JF; Perry, AC; Leblanc, B; Williams, R; Clark, M; Bamman, MM (Nov 1995). "The effects of albuterol and isokinetic exercise on the quadriceps muscle group". Medicine and Science in Sports and Exercise. 27 (11): 1471–6. PMID 8587482. doi:10.1249/00005768-199511000-00002.
- Caruso, J. (20 January 2005). "Albuterol aids resistance exercise in reducing unloading-induced ankle extensor strength losses". Journal of Applied Physiology. 98 (5): 1705–1711. PMID 15640389. doi:10.1152/japplphysiol.01015.2004. Archived from the original on 27 August 2016.
- Caruso, John F.; Hamill, John L.; De Garmo, Nicole (2005). "Oral Albuterol Dosing During the Latter Stages of a Resistance Exercise Program". The Journal of Strength and Conditioning Research. 19 (1): 102–7. PMID 15705021. doi:10.1519/R-14793.1.
- Caruso, JF; Hamill, JL; Yamauchi, M; Mercado, DR; Cook, TD; Keller, CP; Montgomery, AG; Elias, J (Jun 2004). "Albuterol helps resistance exercise attenuate unloading-induced knee extensor losses". Aviation, Space, and Environmental Medicine. 75 (6): 505–11. PMID 15198276.
- Baselt, R. (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Biomedical Publications. pp. 33–35. ISBN 0-9626523-6-9.
- Berges, Rosa; S; V; F; M; F; M; D (2000). "Discrimination of Prohibited Oral Use of Salbutamol from Authorized Inhaled Asthma Treatment". Clinical Chemistry. 46 (9): 1365–75. PMID 10973867. Archived from the original on 2011-07-17.
- Schweizer, C; Saugy, M; Kamber, M (2004). "Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete". Clin. J. Sport Med. 14 (5): 312–315. PMID 15377972. doi:10.1097/00042752-200409000-00018. Archived from the original on 2012-10-05.
- Liewluck, Teerin; Selcen, Duygu; Engel, Andrew G. (November 2011). "Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia". Muscle & Nerve. 44 (5): 789–794. PMC . PMID 21952943. doi:10.1002/mus.22176. Archived from the original on 2015-12-08.
- Van Meerbeke, J. P.; Sumner, C. J. (2011). "Progress and promise: The current status of spinal muscular atrophy therapeutics". Discovery medicine. 12 (65): 291–305. PMID 22031667.
- Lewelt, A.; Newcomb, T. M.; Swoboda, K. J. (2011). "New Therapeutic Approaches to Spinal Muscular Atrophy". Current Neurology and Neuroscience Reports. 12 (1): 42–53. PMC . PMID 22134788. doi:10.1007/s11910-011-0240-9.
- Plumb, Donald C. (2011). "Albuterol Sulfate". Plumb's Veterinary Drug Handbook (7th ed.). Stockholm, Wisconsin; Ames, Iowa: Wiley. pp. 24–25. ISBN 9780470959640.
- Clarke, Kathy W.; Trim, Cynthia M. (2013-06-28). Veterinary Anaesthesia E-Book. Elsevier Health Sciences. p. 612. ISBN 9780702054235. Archived from the original on 2017-09-08.
- Cote, Etienne (2014-12-09). "Albuterol Toxicosis". Clinical Veterinary Advisor - E-Book: Dogs and Cats. Elsevier Health Sciences. pp. 45–46. ISBN 9780323240741. Archived from the original on 2017-09-08.